Ipamorelin: one short, selective pulse

The short version

Ipamorelin is a very small synthetic peptide — five amino acids — that tells the pituitary gland to release a burst of growth hormone. It does this by activating the ghrelin receptor, the same switch the stomach hormone ghrelin uses. That is a different switch from the one GHRH analogues like sermorelin and CJC-1295 press, which is exactly why the two are so often paired.

Its defining feature is selectivity. Older peptides in the same family also nudged up cortisol (a stress hormone) and prolactin. Ipamorelin, in the studies that first described it, largely did not ^[6].

Its second defining feature is that it is quick. In healthy volunteers the growth-hormone response showed up as one distinct spike about 40 minutes after dosing, and the peptide itself was mostly cleared within a couple of hours ^[4]. That is a beat, not a background level.

The honest headline is that almost all of the evidence is preclinical or short-term, and the one real human efficacy trial did not work out.

What it is

Ipamorelin is a synthetic pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. The alpha-aminoisobutyric acid at position one and the two D-amino acids are not decoration: they make the molecule resistant to the proteases that would otherwise chew through a natural peptide in minutes. It was derived from the earlier compound GHRP-1 by removing a central Ala-Trp dipeptide, and it also circulates under the development code NNC 26-0161.

Structurally it belongs to the growth hormone secretagogue family and functionally it is a selective agonist of the ghrelin / growth hormone secretagogue receptor, GHS-R1a. It has never been approved as a drug for any indication, anywhere, and is sold only as a research chemical. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list following the nominator's withdrawal, and reviewed it at the October 2024 Pharmacy Compounding Advisory Committee meeting; it is not an approved bulk substance for compounding. It is prohibited in sport at all times under WADA category S2, and accredited laboratories can detect it in urine.

How it works: the ghrelin side of the pituitary

Pituitary somatotrophs — the cells that manufacture growth hormone — carry at least two independent triggers. One is the GHRH receptor, which signals through Gs and cAMP. The other is GHS-R1a, the ghrelin receptor, which signals through a calcium-linked pathway. Ipamorelin binds the second.

Because the two triggers are independent, their effects are complementary rather than duplicative; co-activating both receptors in transfected cells produced roughly double the cAMP response of GHRH-receptor activation alone ^[20]. That is the entire mechanistic basis for pairing ipamorelin with a GHRH analogue, and it is why the CJC-1295 / ipamorelin combination exists as a category at all.

The selectivity claim is the interesting part. In its founding characterisation ipamorelin released growth hormone potently in primary rat pituitary cells, anaesthetised rats and conscious swine — with a swine ED50 of 2.3 nmol/kg against 3.9 nmol/kg for GHRP-6 — yet did not raise ACTH or cortisol above the level seen with GHRH even at doses more than 200-fold above its growth-hormone ED50 ^[6]. Worth stating the caveat in the same breath: that characterisation was acute. It says nothing about what happens to receptor sensitivity, or to anything else, over months.

Ipamorelin's receptor is not confined to the pituitary. GHS-R1a is also expressed on enteric and vagal neurons involved in gastric motility, on pancreatic islet cells, and in the hypothalamic circuitry that regulates appetite — which is why appetite and gut effects turn up in the safety discussion rather than being filed as off-topic.

What the research shows

Human pharmacokinetics are thin but clean. Population PK/PD modelling in healthy male volunteers (eight per dose level, five 15-minute intravenous infusions spanning 4.21–140.45 nmol/kg) showed dose-proportional kinetics with a terminal half-life of about 2 hours, clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg. The growth-hormone response peaked at roughly 0.67 h — about 40 minutes — after dosing, as a single discrete pulse ^[4]. This is one of the only human ipamorelin datasets in existence.

The one Phase 2 trial missed. In a randomised, controlled proof-of-concept study, 114 adults undergoing open or laparoscopic bowel resection received 0.03 mg/kg intravenously twice daily for up to seven days. Median time to first tolerated meal was 25.3 hours with ipamorelin against 32.6 hours with placebo — a difference that did not reach statistical significance (p=0.15). Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of placebo ^[3]. The trial is the defining human efficacy and safety anchor for this compound, and what it anchors is a negative result.

Preclinical bone data are dose-dependent and instructive. Subcutaneous ipamorelin at 18, 90 and 450 micrograms per day, divided three times daily for 15 days, raised the longitudinal bone growth rate of adult female Sprague-Dawley rats from 42 micrometres/day on vehicle to 44, 50 and 52 micrometres/day respectively — with no measurable change in total IGF-1, IGF binding proteins or bone turnover markers ^[5]. A skeletal effect without a systemic IGF-1 signal points to something local and pulse-driven, and it is a useful counterweight to the assumption that IGF-1 is the only thing worth measuring.

Recent work is peripheral and modest. In a 2024 ferret study, intraperitoneal ipamorelin at 1–3 mg/kg inhibited cisplatin-induced body-weight loss by approximately 24% on the last day of the delayed phase, but produced no anti-emetic effect in either the acute or delayed phase — in contrast to intracerebroventricular anamorelin, which reduced acute emesis by 60% ^[1]. That is the most recent published in-vivo ipamorelin study.

And the reviews are candid. A 2026 narrative review from the USC Keck School of Medicine reported that CJC-1295 combined with ipamorelin improved maximum tetanic tension in a murine glucocorticoid-induced muscle-loss model, while stressing that the evidence is confined to animal studies and that safety and dosing data for ipamorelin remain unknown, with significant further research required before any clinical recommendation ^[7].

Reported effects, cautions and safety

What follows in this first paragraph is anecdotal, not clinical evidence — it is drawn from what people in research-use communities report about themselves, with no verification of what was actually taken, from what source, or at what purity, and it is recorded here because pretending the community record does not exist would be dishonest, not because it carries evidentiary weight. Deeper, more restorative sleep is the most frequently reported benefit, often described as arriving within the first week or two; vivid dreams in the early weeks are reported almost as often and usually described as settling down. Faster physical recovery and reduced post-training soreness are frequently reported. A gradual shift toward leaner body composition over roughly weeks five to twelve is reported occasionally, always confounded by whatever else the person was doing with diet and training. On the adverse side, transient facial flushing or a warm head-rush within roughly 5–15 minutes of injection is frequently reported and often compared to a niacin flush; tingling or numbness in the hands and feet, mild water retention and puffiness, increased hunger in the hours after dosing, injection-site redness or itching, and early lightheadedness are all reported occasionally. Several accounts describe the perceived effects fading after three to four months of continuous use. None of this has been measured under controlled conditions.

The cited safety picture is a different kind of document, and it divides cleanly into what is known and what is merely reasoned.

Chronic cardiovascular safety is genuinely uncharacterised. An integrated 28-day preclinical safety-pharmacology study of GSK894281 — a structurally distinct GHS-R1a agonist in the same receptor class — found dose-dependent myocardial degeneration and necrosis in rats, visible on histopathology and electron microscopy and accompanied by elevated serum heart-type fatty-acid-binding protein at the highest doses, while serum cardiac troponin was not elevated ^[2]. Ipamorelin was not the compound tested, and no equivalent long-duration cardiovascular study of ipamorelin exists in any species. This is a class-level signal, and it is the reason chronic systemic dosing deserves scrutiny rather than reassurance.

The IGF-1 and proliferation concern is mechanistic, not observed. Growth hormone drives hepatic IGF-1 production, and IGF-1 is a well-characterised mitogen. Since ipamorelin's whole purpose is to raise growth-hormone pulse amplitude ^[6], sustained protocols raise a theoretical concern about proliferative activity in pre-existing or occult tumours. No ipamorelin carcinogenicity or tumour-promotion study exists in humans; nothing has been observed, because nothing has been looked for.

Glucose handling is doubly complicated. Growth hormone is a counter-regulatory hormone that reduces peripheral insulin sensitivity, and ipamorelin additionally has a direct, growth-hormone-independent effect on pancreatic islet cells in ex vivo tissue. The net glycemic effect in someone with pre-existing insulin dysregulation is therefore unpredictable, and no human glycemic data exist at research-use exposures.

Appetite is a class effect, not a bug. Ghrelin-receptor agonists activate hypothalamic feeding circuits by design, and preclinical work shows ipamorelin can increase adiposity and leptin partly independently of the growth-hormone axis. That complicates any simple fat-loss narrative built on this compound.

And the evidence base itself is the caution. The complete controlled human record is one Phase 2 trial over at most seven days of intravenous dosing ^[3] plus an acute single-dose PK study in eight subjects per level ^[4]. The dominant route in off-label use — subcutaneous self-administration of reconstituted research-grade powder of unverified identity, purity and sterility — has no published safety or pharmacokinetic characterisation at all.

The one genuine relative advantage is worth keeping: unlike GHRP-6 and GHRP-2, ipamorelin did not meaningfully raise ACTH, cortisol or prolactin even at doses far above its growth-hormone ED50 ^[6]. That removes a specific concern. It does not remove the others.

Where it fits in the growth hormone axis

Ipamorelin is the amplitude answer. It does not touch the GHRH pathway, it does not raise a baseline, and it does not linger. It produces one clean, selective pulse and then leaves — a two-hour half-life and a 40-minute peak ^[4] describe a compound built to be a beat rather than a background.

That makes it the natural partner for a long-acting GHRH analogue and a poor stand-alone if the goal is sustained exposure. It also makes it the compound on this site with the widest gap between marketing and evidence: promotion for anti-aging, fat loss and muscle gain rests on mechanism, short rodent studies and a murine combination result ^[7], while the only controlled human efficacy trial reported a negative primary endpoint ^[3]. Both of those things are true at once, and any honest reading has to hold them together.

Next: how a GHRH analogue answers the same question by stretching the clock instead — CJC-1295 — or compare these peptides side by side.